相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Long-Term Safety and Efficacy Data of Golodirsen in Ambulatory Patients with Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping: A First-in-human, Multicenter, Two-Part, Open-Label, Phase 1/2 Trial
Laurent Servais et al.
NUCLEIC ACID THERAPEUTICS (2022)
Antisense and Gene Therapy Options for Duchenne Muscular Dystrophy Arising from Mutations in the N-Terminal Hotspot
Harry Wilton-Clark et al.
GENES (2022)
Ataluren-Promising Therapeutic Premature Termination Codon Readthrough Frontrunner
Sylwia Michorowska
PHARMACEUTICALS (2021)
Gene Therapy for Duchenne Muscular Dystrophy
Nertiyan Elangkovan et al.
Journal of Neuromuscular Diseases (2021)
Exon-Skipping in Duchenne Muscular Dystrophy
Shin’ichi Takeda et al.
Journal of Neuromuscular Diseases (2021)
Ethnicity-related DMD Genotype Landscapes in European and Non-European Countries
Rita Selvatici et al.
NEUROLOGY-GENETICS (2021)
The DMD gene and therapeutic approaches to restore dystrophin
Fernanda Fortunato et al.
NEUROMUSCULAR DISORDERS (2021)
Duchenne muscular dystrophy
Dongsheng Duan et al.
NATURE REVIEWS DISEASE PRIMERS (2021)
Casimersen: First Approval
Matt Shirley
DRUGS (2021)
Safety, tolerability, and pharmacokinetics of casimersen in patients with Duchenne muscular dystrophy amenable to exon 45 skipping: A randomized, double-blind, placebo-controlled, dose-titration trial
Kathryn R. Wagner et al.
MUSCLE & NERVE (2021)
Theragnosis for Duchenne Muscular Dystrophy
Leonela Luce et al.
FRONTIERS IN PHARMACOLOGY (2021)
EMQN best practice guidelines for genetic testing in dystrophinopathies
Carl Fratter et al.
EUROPEAN JOURNAL OF HUMAN GENETICS (2020)
Optimization of antisense-mediated exon skipping for Duchenne muscular dystrophy
Kasia Dzierlega et al.
GENE THERAPY (2020)
Safety and effectiveness of ataluren: comparison of results from the STRIDE Registry and CINRG DMD Natural History Study
Eugenio Mercuri et al.
JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH (2020)
The Genetic Landscape of Dystrophin Mutations in Italy: A Nationwide Study
Marcella Neri et al.
FRONTIERS IN GENETICS (2020)
Safety, Tolerability, and Efficacy of Viltolarsen in Boys With Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping A Phase 2 Randomized Clinical Trial
Paula R. Clemens et al.
JAMA NEUROLOGY (2020)
Therapeutic Strategies for Duchenne Muscular Dystrophy: An Update
Chengmei Sun et al.
GENES (2020)
Transport of Ca(2+)and Ca2+-dependent permeability transition in heart mitochondria in the early stages of Duchenne muscular dystrophy
Mikhail Dubinin et al.
BIOCHIMICA ET BIOPHYSICA ACTA-BIOENERGETICS (2020)
The position of nonsense mutations can predict the phenotype severity: A survey on the DMD gene
Annalaura Torella et al.
PLOS ONE (2020)
Clinical Phenotypes of DMD Exon 51 Skip Equivalent Deletions: A Systematic Review
Megan A. Waldrop et al.
JOURNAL OF NEUROMUSCULAR DISEASES (2020)
Update in Duchenne and Becker muscular dystrophy
Megan A. Waldrop et al.
CURRENT OPINION IN NEUROLOGY (2019)
Genetic analysis of 1051 Chinese families with Duchenne/Becker Muscular Dystrophy
Xiangdong Kong et al.
BMC MEDICAL GENETICS (2019)
Mutational spectrum of Duchenne muscular dystrophy in Spain: Study of 284 cases
I. Vieitez et al.
NEUROLOGIA (2017)
Eteplirsen in the treatment of Duchenne muscular dystrophy
Kenji Rowel Q. Lim et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2017)
The importance of genetic diagnosis for Duchenne muscular dystrophy
Annemieke Aartsma-Rus et al.
JOURNAL OF MEDICAL GENETICS (2016)
Clinical potential of ataluren in the treatment of Duchenne muscular dystrophy
John Hyun Namgoong et al.
DEGENERATIVE NEUROLOGICAL AND NEUROMUSCULAR DISEASE (2016)
The TREAT-NMD DMD Global Database: Analysis of More than 7,000 Duchenne Muscular Dystrophy Mutations
Catherine L. Bladen et al.
HUMAN MUTATION (2015)
Duchenne Muscular Dystrophy: From Diagnosis to Therapy
Maria Sofia Falzarano et al.
MOLECULES (2015)
DMD Mutations in 576 Dystrophinopathy Families: A Step Forward in Genotype-Phenotype Correlations
Jonas Juan-Mateu et al.
PLOS ONE (2015)
Duchenne and Becker Muscular Dystrophies
Kevin M. Flanigan
NEUROLOGIC CLINICS (2014)
Genotype and phenotype characterization in a large dystrophinopathic cohort with extended follow-up
Francesca Magri et al.
JOURNAL OF NEUROLOGY (2011)
Mutation spectrum of the dystrophin gene in 442 Duchenne/Becker muscular dystrophy cases from one Japanese referral center
Yasuhiro Takeshima et al.
JOURNAL OF HUMAN GENETICS (2010)
Deletion mutations in Duchenne muscular dystrophy (DMD) in Western Saudi children
Mohammed T. Tayeb
SAUDI JOURNAL OF BIOLOGICAL SCIENCES (2010)
Transcriptional Behavior of DMD Gene Duplications in DMD/BMD Males
F. Gualandi et al.
HUMAN MUTATION (2009)
Mutational Spectrum of DMD Mutations in Dystrophinopathy Patients: Application of Modern Diagnostic Techniques to a Large Cohort
Kevin M. Flanigan et al.
HUMAN MUTATION (2009)
Genotype-Phenotype Analysis in 2,405 Patients with a Dystrophinopathy Using the UMD-DMD Database: A Model of Nationwide Knowledgebase
Sylvie Tuffery-Giraud et al.
HUMAN MUTATION (2009)
Entries in the Leiden Duchenne muscular dystrophy mutation database: An overview of mutation types and paradoxical cases that confirm the reading-frame rule
Annemieke Aartsma-Rus et al.
MUSCLE & NERVE (2006)
Deletion and duplication screening in the DMD gene using MLPA
T Lalic et al.
EUROPEAN JOURNAL OF HUMAN GENETICS (2005)
Duchenne and Becker muscular dystrophy: From gene diagnosis to molecular therapy
M Matsuo
IUBMB LIFE (2002)